Dipeptidyl peptidase-4 (DPP-4) inhibitory activity and glucagon-like peptide (GLP-1) secretion in arsenically safe pigmented red rice (Oryza sativa L.) and its product

被引:0
|
作者
Duyi Samyor
Danielle Calderwood
Manus Carey
Amit B. Das
Brian D. Green
Sankar C. Deka
机构
[1] Tezpur University,Department of Food Engineering and Technology
[2] Queen’s University Belfast,Institute for Global Food Security, School of Biological Sciences
来源
Journal of Food Science and Technology | 2022年 / 59卷
关键词
Pigmented rice; Rice bran; DPP-4; Antidiabetic; GLP-1;
D O I
暂无
中图分类号
学科分类号
摘要
Inhibition of DPP-4 and stimulation of GLP-1 secretion are therapeutic strategies for controlling glycaemia in type 2 diabetes. The present study assessed the DPP-4 inhibitory activity and GLP-1 secretory action of pigmented and non-pigmented rice (Oryza sativa L.), along with an extruded food product. Cereal-based extruded food products, with or without passion fruit powder, were prepared from red rice using a twin extruder. Optimal extrusion conditions were determined using a CCD of response surface methodology resulting in optimal conditions to be 97.5 °C, a screw speed of 250 rpm, feed moisture of 25.2% and addition of 11.25% passion fruit powder. Samples were sequentially extracted in n-hexane, ethanol (50%) and water. Ethanol/water (50:50) extracts of rice bran significantly inhibited DPP-4 activity by 70.48 ± 1.06%, comparing favourably with RR (42.55 ± 0.84%), PRR (35.91 ± 1.27%) and PA (29.14 ± 1.23%). DPP-4 inhibitory activity was retained in both extruded products albeit at reduced levels. GLP-1 secretion was stimulated mostly by extruded products extracted with n-hexane or ethanol which upregulated basal secretion by 6.1-fold and 4.2-fold, respectively. ICP-MS results showed that extruded food items have a lower arsenic content. In conclusion, there are potential opportunities for the nutraceuticals and functional food products using pigmented red rice.
引用
收藏
页码:4016 / 4024
页数:8
相关论文
共 36 条
  • [1] Dipeptidyl peptidase-4 (DPP-4) inhibitory activity and glucagon-like peptide (GLP-1) secretion in arsenically safe pigmented red rice (Oryza sativa L.) and its product
    Samyor, Duyi
    Calderwood, Danielle
    Carey, Manus
    Das, Amit B.
    Green, Brian D.
    Deka, Sankar C.
    JOURNAL OF FOOD SCIENCE AND TECHNOLOGY-MYSORE, 2022, 59 (10): : 4016 - 4024
  • [2] Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to Glucagon-Like Peptide-1 (GLP-1) agonists: No
    Madsbad, Sten
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2012, 23 (02) : 132 - 136
  • [3] Glucagon-like peptide-1 levels and dipeptidyl peptidase-4 activity in type 2 diabetes
    Senyigit, Abdulhalim
    Tabak, Omur
    Orbanoglu, Timur
    Karadag, Aytac
    Ugurlu, Serdal
    Uzun, Hafize
    Konukoglu, Dihlar
    CLINICAL AND INVESTIGATIVE MEDICINE, 2017, 40 (05): : E188 - E199
  • [4] Altered circulating concentrations of active glucagon-like peptide (GLP-1) and dipeptidyl peptidase 4 (DPP4) in obese subjects and their association with insulin resistance
    Ahmed, Radwan H.
    Huri, Hasniza Zaman
    Muniandy, Sekaran
    Al-Hamodi, Zaid
    Al-absi, Boshra
    Alsalahi, Abdulsamad
    Razif, Muhammad F. M.
    CLINICAL BIOCHEMISTRY, 2017, 50 (13-14) : 746 - 749
  • [5] Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: Yes
    Scheen, Andre J.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2012, 23 (02) : 126 - 131
  • [6] Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion
    Lugari, R
    Dei Cas, A
    Ugolotti, D
    Barilli, AL
    Camellini, C
    Ganzerla, GC
    Luciani, A
    Salerni, B
    Mittenperger, F
    Nodari, S
    Gnudi, A
    Zandomeneghi, R
    HORMONE AND METABOLIC RESEARCH, 2004, 36 (02) : 111 - 115
  • [7] Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review
    Hong, Dongzhe
    Si, Lei
    Jiang, Minghuan
    Shao, Hui
    Ming, Wai-kit
    Zhao, Yingnan
    Li, Yan
    Shi, Lizheng
    PHARMACOECONOMICS, 2019, 37 (06) : 777 - 818
  • [8] Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review
    Dongzhe Hong
    Lei Si
    Minghuan Jiang
    Hui Shao
    Wai-kit Ming
    Yingnan Zhao
    Yan Li
    Lizheng Shi
    PharmacoEconomics, 2019, 37 : 777 - 818
  • [9] Glucagon Like Peptide-1 (GLP-1) Does Not Cause Vasodilation Even When Dipeptidyl Peptidase 4 (DPP4) is Inhibited
    Devin, Jessica K.
    Pretorius, Mias
    Billings, Frederic T.
    Nian, Hui
    Brown, Nancy J.
    HYPERTENSION, 2013, 62 (03)
  • [10] Comparative Effectiveness of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors and Human Glucagon-Like Peptide-1 (GLP-1) Analogue as Add-On Therapies to Sulphonylurea among Diabetes Patients in the Asia-Pacific Region: A Systematic Review
    Wong, Martin C. S.
    Wang, Harry H. X.
    Kwan, Mandy W. M.
    Zhang, Daisy D. X.
    Liu, Kirin Q. L.
    Chan, Sky W. M.
    Fan, Carmen K. M.
    Fong, Brian C. Y.
    Li, Shannon T. S.
    Griffiths, Sian M.
    PLOS ONE, 2014, 9 (03):